Decision is delayed on whether Avastin can stay a breast cancer drug

09/19/2010 | Reuters

The FDA extended until Dec. 17 a review of Genentech's two applications for Avastin as a combination treatment with other types of chemotherapy for breast cancer. The move comes after the company submitted additional information on the drug's wider uses. The agency has not decided whether to remove Avastin's marketing approval for breast cancer, as recommended by advisers.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX